NCT05363605: A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours |
|
|
| Terminated | 1/2 | 6 | US, RoW | [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab | Fusion Pharmaceuticals Inc. | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer | 09/23 | 09/23 | | |